Search | Clinical Trials Finder

Conditions: Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Interventions: Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88; Drug
Lead sponsor: Pancreatic Cancer Action Network; Other
Eligibility: 18 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 25
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 18 more

Conditions: Prostate Cancer Patients, Non-castrate Prostate Cancer, Recurrent Prostate Cancer, Oligometastatic Prostate Cancer (OMPC)
Interventions: pTVG-HP DNA vaccine, Anti-PD-1 monoclonal antibody; Biological · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Interventions: Dabrafenib, Spartalizumab, Therapeutic Conventional Surgery, Trametinib; Drug · Biological · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma
Interventions: Spartalizumab, Placebo, Dabrafenib, Trametinib; Biological · Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 12
States / cities: Encinitas, California • Orange, California • San Francisco, California + 9 more

Conditions: Glioblastoma, Glioblastoma Multiforme
Interventions: Nivolumab, Anti-GITR Monoclonal Antibody MK-4166, IDO1 inhibitor INCB024360, Ipilimumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-small Cell Lung Cancer
Interventions: PDR001, Cisplatin, Gemcitabine, Pemetrexed, Carboplatin, Paclitaxel, Canakinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 5
States / cities: Fayetteville, Arkansas • Santa Monica, California • Stanford, California + 2 more

Conditions: Advanced Cancer, Melanoma, Non-Small Cell Lung Cancer
Interventions: BMS-986205, Nivolumab, Ipilimumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 627 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 15
States / cities: Tucson, Arizona • La Jolla, California • Tampa, Florida + 11 more

Conditions: Multiple Myeloma
Interventions: Autologous Stem Cell Transplant, Melphalan, Lenalidomide, MK-3475; Procedure · Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Milwaukee, Wisconsin

Conditions: Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma, Soft Tissue Sarcoma, Ovarian Adenocarcinoma, Advanced Well-differentiated Neuroendocrine Tumors, Diffuse Large B Cell Lymphoma
Interventions: PDR001, LAG525; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 20
States / cities: San Francisco, California • Port Saint Lucie, Florida • Athens, Georgia + 15 more

Conditions: Melanoma
Interventions: MK-3475, Peginterferon alfa-2b; Drug
Lead sponsor: Hassane M. Zarour, MD; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma
Interventions: GB1275, nab-paclitaxel and gemcitabine, pembrolizumab; Drug
Lead sponsor: GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: San Francisco, California • Aurora, Colorado • St Louis, Missouri + 4 more

Conditions: Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal SCC, Gastrointestinal Stromal Tumors, Colorectal Cancer
Interventions: TNO155, Spartalizumab, Ribociclib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
Interventions: HST-1011, Cemiplimab; Drug · Biological
Lead sponsor: HotSpot Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 8
States / cities: Sarasota, Florida • Las Vegas, Nevada • New York, New York + 5 more

Conditions: Solid Tumors
Interventions: LHC165, PDR001; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Los Angeles, California • Houston, Texas

Conditions: Melanoma, Non-small Sell Lung Cancer (NSCLC), Triple Negative Breast Cancer, Anaplastic Thyroid Cancer, Other Solid Tumors
Interventions: PDR001; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 6
States / cities: Baltimore, Maryland • Boston, Massachusetts • Portland, Oregon + 3 more

Conditions: Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer, HER2-Negative Breast Cancer, Metastatic Epithelial Ovarian Cancer
Interventions: Ribociclib, PDR001, Fulvestrant; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Interventions: decitabine, spartalizumab, sabatolimab, azacitidine, venetoclax, INQOVI (oral decitabine); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 99 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Portland, Oregon • Salt Lake City, Utah

Conditions: Gastrointestinal Stromal Tumors
Interventions: Pembrolizumab, Epacadostat; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Ann Arbor, Michigan • New York, New York

Conditions: Solid Tumor
Interventions: CRB-601 monoclonal antibody, Anti-PD-1 monoclonal antibody; Drug
Lead sponsor: Corbus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 20
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 15 more

Conditions: Advanced Solid Tumors
Interventions: BLZ945, PDR001; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 4
States / cities: Boston, Massachusetts • Nashville, Tennessee • Houston, Texas + 1 more

Conditions: Melanoma, Unresectable Solid Tumors, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Antineoplastic Agents, Immunological, Antineoplastic Agents, Immune Checkpoint Inhibitors, Molecular Mechanisms of Pharmacological Action, Nivolumab
Interventions: nivolumab, BMS-986253, Stereotactic Body Radiotherapy (SBRT); Drug · Radiation
Lead sponsor: Yana Najjar; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois • Pittsburgh, Pennsylvania

Conditions: Carcinoma, Renal Cell
Interventions: DFF332, RAD001, PDR001, NIR178; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Duarte, California • Boston, Massachusetts • St Louis, Missouri + 2 more

Conditions: Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Bevacizumab, Biopsy Procedure, Biospecimen Collection, Chemotherapy, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Monitoring, Positron Emission Tomography, Surveillance, Tremelimumab; Drug · Biological · Procedure + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 13
States / cities: Goodyear, Arizona • Corona, California • Duarte, California + 10 more

Conditions: Solid Tumors
Interventions: BI 1831169, anti-PD-1 antibody; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 10
States / cities: Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 7 more

Search by objective public record fields.

A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Treatment of Advanced Melanoma With MK-3475 and Peginterferon

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Epacadostat and Pembrolizumab in Patients With GIST

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)